about
Antagonists of the kappa-opioid receptor enhance allodynia in rats and mice after sciatic nerve ligationThe glutamatergic system as a target for neuropathic pain reliefAntagonistic effect of cyproheptadine on neuroleptic-induced catalepsyEffects of pilocarpine- and kainate-induced seizures on thyrotropin-releasing hormone biosynthesis and receptors in the rat brainInterleukin-1 alpha has antiallodynic and antihyperalgesic activities in a rat neuropathic pain modelPain inhibition by endomorphins.Delta-opioid receptor analgesia is independent of microglial activation in a rat model of neuropathic painExpression profiling of genes modulated by minocycline in a rat model of neuropathic painOpioids in chronic pain.Full inhibition of spinal FAAH leads to TRPV1-mediated analgesic effects in neuropathic rats and possible lipoxygenase-mediated remodeling of anandamide metabolism.Synthesis and biological evaluation of compact, conformationally constrained bifunctional opioid agonist - neurokinin-1 antagonist peptidomimetics.The role of melanocortins and their receptors in inflammatory processes, nerve regeneration and nociception.Anandamide, Acting via CB2 Receptors, Alleviates LPS-Induced Neuroinflammation in Rat Primary Microglial Cultures.PD98059 Influences Immune Factors and Enhances Opioid Analgesia in Model of NeuropathyOpioids in neuropathic pain.Blockade of Toll-Like Receptors (TLR2, TLR4) Attenuates Pain and Potentiates Buprenorphine Analgesia in a Rat Neuropathic Pain Model.Dataset of botulinum toxin A influence on interleukins under neuropathy.Blockade of P2X4 Receptors Inhibits Neuropathic Pain-Related Behavior by Preventing MMP-9 Activation and, Consequently, Pronociceptive Interleukin Release in a Rat Model.The role of nociceptin and dynorphin in chronic pain: implications of neuro-glial interaction.Modulation of neuropathic-pain-related behaviour by the spinal endocannabinoid/endovanilloid system.Importance of glial activation in neuropathic pain.Mechanisms and pharmacology of diabetic neuropathy - experimental and clinical studies.Neuronal and immunological basis of action of antidepressants in chronic pain - clinical and experimental studies.The effect of lesions of raphe nuclei on the cataleptic action of neuroleptics.The influence of dopamine-beta-hydroxylase inhibitors on avoidance reaction in rat.Pharmacological kynurenine 3-monooxygenase enzyme inhibition significantly reduces neuropathic pain in a rat model.The effect of L-DOPA and L-5-hydroxytryptophan on the pentetrazole seizures in rats after lesions of the median raphe nucleus and substantia nigra.Sedative action of low doses of dopaminergic agents.The effects of excitatory amino acids on proenkephalin and prodynorphin mRNA levels in the hippocampal dentate gyrus of the rat; an in situ hybridization study.Release of opioid peptides from the spinal cord of rats subjected to chronic pain.Kappa opioid receptor agonists inhibit the pilocarpine-induced seizures and toxicity in the mouse.The effects of cocaine-induced seizures on the proenkephalin mRNA level in the mouse hippocampus: a possible involvement of the nitric oxide pathway.Expression of proenkephalin (PENK) mRNA in inflammatory leukocytes during experimental peritonitis in Swiss mice.Minocycline enhances the effectiveness of nociceptin/orphanin FQ during neuropathic pain.Changes induced by formalin pain in central alpha1-adrenoceptor density are modulated by adenosine receptor agonists.Agonist-dependent attenuation of mu-opioid receptor-mediated G-protein activation in the dorsal root ganglia of neuropathic rats.Peripheral antinociceptive effects of MC4 receptor antagonists in a rat model of neuropathic pain - a biochemical and behavioral study.Efficacy of tramadol in combination with doxepin or venlafaxine in inhibition of nociceptive process in the rat model of neuropathic pain: an isobolographic analysis.Minocycline reduces the injury-induced expression of prodynorphin and pronociceptin in the dorsal root ganglion in a rat model of neuropathic pain.Glial inhibitors influence the mRNA and protein levels of mGlu2/3, 5 and 7 receptors and potentiate the analgesic effects of their ligands in a mouse model of neuropathic pain.
P50
Q24672417-48757E7A-130C-4795-AFFA-6AAB20E67405Q27006077-289CC9B6-AD74-4253-B1F4-B67B9242B08DQ28339875-A36A4978-172B-4158-A427-63E1E408A393Q28370634-CDC7EADB-117A-4B1B-B271-541B5724C3F9Q28571428-877C3526-FACE-47CE-9EBE-137C6BEF639FQ33838465-A62DF69B-34AD-4CDA-A13E-13D7B1C72A06Q34020583-8C025F0A-D60B-45FD-8407-870138C675A0Q34039604-B6081B78-2EDC-46E1-8D87-51DB2C8445E8Q34430627-576625FB-51B5-4381-ABAA-6F3F02B3CE74Q34661844-27352275-3C46-4D85-9579-459ABBA5CE91Q35107996-EF3F5944-C1EB-4B8E-8232-333E5E9705B7Q35150459-E1FF1FD9-9975-4F85-85B2-59A57751E88FQ35674014-57623E94-467F-4A59-893A-84D316CC1636Q35795123-99AC3692-E52A-4A18-94C4-3DF95EFA9FEDQ36264640-9EADE2BC-D63A-4FB7-A6F3-6AC5E4AAD01DQ36453875-6BC64FA3-4E32-4B85-A8BF-052E08743F19Q37438555-9C6149D0-24A1-4E0F-A352-AA6DDEB4BDA8Q37659337-F0D3E263-0E55-4928-AA02-75EEDF5D32EAQ37863309-EF47093C-2676-47EA-BAED-46EB00194CB3Q38056397-351F7F59-F088-40B7-A626-E35DCC1EA532Q38090291-8D1C2489-2590-4179-A292-ADE19AB1ADF8Q38189559-70B1D959-1821-4A9A-A078-B1C1BFD39D2AQ38189561-49996E31-4ADB-40C4-94B0-17E73E9731F7Q39180185-D4E562A5-2BE0-46C7-94EA-5AF71D4DD0B4Q40349467-A59576CE-1478-402B-8D1A-771E8F0D17F7Q40366999-397850AB-057F-498F-9525-4BBD0569578CQ40738505-54FE3D9F-53D3-45A1-98F3-A384BD368E22Q41052649-573948E6-FEA0-4858-ACA2-993CB6FF47A9Q41958805-EC2484C0-59CC-45F7-B0CB-30A1C3630FCAQ41972433-A8B9126E-8C8A-46A6-A60D-814C05C70A7AQ42281353-23616728-88DD-49F2-A6AC-25C5B8B8D186Q42283489-4C001BFC-7D0C-4564-A8F0-B6EFF87608F6Q42520839-7E4ADDD6-7770-438A-9D41-23A74F9CBCAAQ42905505-DE4E2F7C-E370-48A4-BA1A-94105FCBC227Q43121468-5A44B830-EB09-4E03-833B-55B875866F6EQ43137746-B8413CAC-7C60-49E8-9AF4-F975DDA1FF56Q43191765-F480E627-E643-4C9E-82EF-C9EDABF8361EQ43197267-8D3BAC9C-1923-492E-8916-EB4E210B0AE2Q43229604-FBFA62BA-C0E9-4B52-B3F6-9B7C9E2EBF90Q43270943-3765BDAC-D78F-4FB6-A130-D28788EBCA65
P50
description
Polish pharmacologist
@en
Pools farmacologe
@nl
polska farmakolog
@pl
name
Barbara Przewłocka
@ast
Barbara Przewłocka
@ca
Barbara Przewłocka
@cs
Barbara Przewłocka
@en
Barbara Przewłocka
@es
Barbara Przewłocka
@gl
Barbara Przewłocka
@hr
Barbara Przewłocka
@hsb
Barbara Przewłocka
@it
Barbara Przewłocka
@nl
type
label
Barbara Przewłocka
@ast
Barbara Przewłocka
@ca
Barbara Przewłocka
@cs
Barbara Przewłocka
@en
Barbara Przewłocka
@es
Barbara Przewłocka
@gl
Barbara Przewłocka
@hr
Barbara Przewłocka
@hsb
Barbara Przewłocka
@it
Barbara Przewłocka
@nl
altLabel
Barbara Elżbieta Przewłocka
@pl
prefLabel
Barbara Przewłocka
@ast
Barbara Przewłocka
@ca
Barbara Przewłocka
@cs
Barbara Przewłocka
@en
Barbara Przewłocka
@es
Barbara Przewłocka
@gl
Barbara Przewłocka
@hr
Barbara Przewłocka
@hsb
Barbara Przewłocka
@it
Barbara Przewłocka
@nl
P106
P1412
P1559
Barbara Przewłocka
@pl
P21
P214
118145067262866631007
P27
P31
P3124
P7859
viaf-101813538
viaf-118145067262866631007